dc.contributor.author | Giovannoni, G | en_US |
dc.contributor.author | Turner, B | en_US |
dc.contributor.author | Gnanapavan, S | en_US |
dc.contributor.author | Offiah, C | en_US |
dc.contributor.author | Schmierer, K | en_US |
dc.contributor.author | Marta, M | en_US |
dc.date.accessioned | 2015-09-03T08:20:29Z | |
dc.date.available | 2015-04-28 | en_US |
dc.date.issued | 2015-07 | en_US |
dc.identifier.issn | 2211-0348 | en_US |
dc.identifier.uri | http://qmro.qmul.ac.uk/xmlui/handle/123456789/8421 | |
dc.format.extent | 329 - 333 | en_US |
dc.relation.ispartof | MULTIPLE SCLEROSIS AND RELATED DISORDERS | en_US |
dc.subject | No evident disease activity | en_US |
dc.subject | NEDA | en_US |
dc.subject | Multiple sclerosis | en_US |
dc.subject | Disease modifying therapy | en_US |
dc.subject | Treating to target | en_US |
dc.subject | Disease activity free | en_US |
dc.title | Is it time to target no evident disease activity (NEDA) in multiple sclerosis? | en_US |
dc.type | Article | |
dc.rights.holder | Licensed with a Creative Commons Attribution Non-Commercial No Derivatives License | |
dc.identifier.doi | 10.1016/j.msard.2015.04.006 | en_US |
pubs.author-url | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000359331400008&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=612ae0d773dcbdba3046f6df545e9f6a | en_US |
pubs.issue | 4 | en_US |
pubs.notes | No embargo | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 4 | en_US |